Precipio Launches New HemeScreen™ Reagent Rental Program
06 avr. 2020 10h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., April 06, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it has launched its HemeScreen™ Reagent Rental (HSRR) program....
First Substantial Customer: Tennessee Oncology Internalizes Precipio’s HemeScreen™
30 sept. 2019 11h10 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that Tennessee Oncology has selected Precipio’s HemeScreen RUO assay as...
Clinical Validations for IV-Cell™ and HemeScreen™ Completed
26 sept. 2019 10h53 HE
|
Precipio, Inc.
Orders expected from several major labs both domestically and internationally NEW HAVEN, Conn., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO),...
NTS Ventures and IHMA Announce a Significant and Important Program Focusing on Antifungal Resistance Surveillance: STAR (Susceptibility Trends in Antifungal Resistance)
12 juin 2019 08h00 HE
|
IHMA Inc
SCHAUMBURG, Ill., June 12, 2019 (GLOBE NEWSWIRE) -- NTS Ventures (NTS), a mycology and antifungal clinical research laboratory and International Health Management Associates, Inc./IHMA Europe Sàrl...
Precipio Signs First Major International Services Contract
29 avr. 2019 08h35 HE
|
Precipio, Inc.
NEW HAVEN, Conn., April 29, 2019 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) today announced that it has signed a services contract with a health care...
Precipio’s HemeScreen™ Adopted by Methodist Health
03 avr. 2019 07h38 HE
|
Precipio, Inc.
NEW HAVEN, Conn., April 03, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that Methodist Hospital, located in Memphis, TN, has selected...
Precipio Expands ICE COLD-PCR™ Menu for Breast, Colon and Endometrial Cancers
23 oct. 2018 09h15 HE
|
Precipio, Inc.
Ultra-sensitive assays for PIK3CA exons 9 & 20 detect mutations that impact critical therapeutic decisions NEW HAVEN, Conn., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Precipio, Inc. (NASDAQ: PRPO),...
Precipio Launches HemeScreen™, a Disruptive, Proprietary Molecular Test for Hematologic Cancers
03 oct. 2018 07h47 HE
|
Precipio, Inc.
Impacts a $100M annual US laboratory market by reducing testing costs through a simple, screening assay NEW HAVEN, Conn., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company...
HiberGene Completes Group B Streptococcus Study with National Maternity Hospital
12 janv. 2017 04h15 HE
|
HiberGene Diagnostics Ltd
DUBLIN, Ireland, Jan. 12, 2017 (GLOBE NEWSWIRE) -- A joint study conducted by Dublin-based molecular diagnostics manufacturer HiberGene and the National Maternity Hospital (NMH), Dublin has found...
HiberGene Launches HG C. Difficile Test
15 déc. 2016 04h55 HE
|
HiberGene Diagnostics Ltd
DUBLIN, Ireland, Dec. 15, 2016 (GLOBE NEWSWIRE) -- HiberGene Diagnostics, a company focussed on applying molecular technology to the infectious disease segment of the diagnostics market, has...